RecruitingMigraine
Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.
Sponsor: Mayo Clinic
You may qualify if…
- ✓ Meets International Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura
- ✓ At least 18 years of age
- ✓ 2- 8 migraine attacks per month
- ✓ Participants should be on a calcitonin gene-related peptide (CGRP)-targeting preventive migraine medication on a stable dose for a) ≥2 months prior to zavegepant treatment if an oral gepant or a monoclonal antibody (mAb) injected monthly, or b) at least two treatments if a mAb injected each 3 months.
- ✓ Atogepant
- ✓ Eptinezumab
- ✓ Erenumab
- ✓ Fremanezumab
You may not qualify if…
- ✕ Primary headache disorders other than migraine (tension-type headache days are allowed)
- ✕ History of hypersensitivity reaction to zavegepant or to any of the components of zavegepant
- ✕ Eligibility Notes
- ✕ Participants may have either episodic or chronic migraine.
- ✕ Prior use of zavegepant and other gepants is permitted.
- ✕ Participants can be using migraine preventive medications/treatments in addition to the CGRP-targeting preventive treatment, as long as those treatments have been stable for at least two months at the time of enrollment.
- ✕ Additional Eligibility Criteria for Participants to Start on Rimegepant for Migraine Prevention
- ✕ History of hypersensitivity reaction to rimegepant or to any of the components of rimegepant.
Where it's recruiting
Arizona
Phoenix
Source: ClinicalTrials.gov · NCT06401642 · last updated 2025-09-09